vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.
Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $5.0M, roughly 1.9× cbdMD, Inc.). cbdMD, Inc. runs the higher net margin — -5.6% vs -265.9%, a 260.2% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -1.9%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-977.3K).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.
CLLS vs YCBD — Head-to-Head
Income Statement — Q2 FY2024 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $5.0M |
| Net Profit | $-25.3M | $-283.1K |
| Gross Margin | — | 59.8% |
| Operating Margin | -181.1% | -5.7% |
| Net Margin | -265.9% | -5.6% |
| Revenue YoY | 375.0% | -1.9% |
| Net Profit YoY | -51.9% | -1975.7% |
| EPS (diluted) | $-0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.0M | ||
| Q3 25 | — | $4.7M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | — | $4.7M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | — | $4.6M | ||
| Q2 24 | $9.5M | $5.2M | ||
| Q1 24 | — | $4.4M |
| Q4 25 | — | $-283.1K | ||
| Q3 25 | — | $-680.0K | ||
| Q2 25 | — | $-895.3K | ||
| Q1 25 | — | $-480.8K | ||
| Q4 24 | — | $15.1K | ||
| Q3 24 | — | $-152.8K | ||
| Q2 24 | $-25.3M | $459.7K | ||
| Q1 24 | — | $-3.0M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.5% | ||
| Q1 25 | — | 62.3% | ||
| Q4 24 | — | 66.5% | ||
| Q3 24 | — | 53.9% | ||
| Q2 24 | — | 65.8% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | — | -5.7% | ||
| Q3 25 | — | -14.5% | ||
| Q2 25 | — | -19.6% | ||
| Q1 25 | — | -10.2% | ||
| Q4 24 | — | -1.7% | ||
| Q3 24 | — | -6.9% | ||
| Q2 24 | -181.1% | -7.4% | ||
| Q1 24 | — | -35.4% |
| Q4 25 | — | -5.6% | ||
| Q3 25 | — | -14.4% | ||
| Q2 25 | — | -19.4% | ||
| Q1 25 | — | -10.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | -3.4% | ||
| Q2 24 | -265.9% | 8.9% | ||
| Q1 24 | — | -68.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.28 | $-0.15 | ||
| Q1 24 | — | $-1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $3.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $9.0M |
| Total Assets | $407.1M | $11.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $2.3M | ||
| Q2 25 | — | $1.1M | ||
| Q1 25 | — | $1.8M | ||
| Q4 24 | — | $2.0M | ||
| Q3 24 | — | $2.5M | ||
| Q2 24 | $149.0M | $2.4M | ||
| Q1 24 | — | $2.1M |
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $7.2M | ||
| Q2 25 | — | $6.1M | ||
| Q1 25 | — | $665.8K | ||
| Q4 24 | — | $1.8M | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | $148.6M | $3.0M | ||
| Q1 24 | — | $3.1M |
| Q4 25 | — | $11.8M | ||
| Q3 25 | — | $10.4M | ||
| Q2 25 | — | $9.9M | ||
| Q1 25 | — | $10.9M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | — | $10.6M | ||
| Q2 24 | $407.1M | $13.8M | ||
| Q1 24 | — | $14.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-812.5K |
| Free Cash FlowOCF − Capex | $27.6M | $-977.3K |
| FCF MarginFCF / Revenue | 290.5% | -19.5% |
| Capex IntensityCapex / Revenue | 13.2% | 3.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-812.5K | ||
| Q3 25 | — | $-240.7K | ||
| Q2 25 | — | $-704.2K | ||
| Q1 25 | — | $-189.5K | ||
| Q4 24 | — | $-317.9K | ||
| Q3 24 | — | $167.4K | ||
| Q2 24 | $28.9M | $289.8K | ||
| Q1 24 | — | $-704.1K |
| Q4 25 | — | $-977.3K | ||
| Q3 25 | — | $-243.6K | ||
| Q2 25 | — | $-705.7K | ||
| Q1 25 | — | $-205.0K | ||
| Q4 24 | — | $-482.3K | ||
| Q3 24 | — | $157.4K | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | — | $-708.7K |
| Q4 25 | — | -19.5% | ||
| Q3 25 | — | -5.2% | ||
| Q2 25 | — | -15.3% | ||
| Q1 25 | — | -4.3% | ||
| Q4 24 | — | -9.4% | ||
| Q3 24 | — | 3.5% | ||
| Q2 24 | 290.5% | — | ||
| Q1 24 | — | -16.2% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | 13.2% | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -21.06× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLLS
Segment breakdown not available.
YCBD
| Sales Channel Directly To Consumer | $3.6M | 72% |
| Sales Channel Through Intermediary | $1.4M | 28% |
